Preferred Label : Nucala;
Origin ID : M000621546;
Related record
https://www.has-sante.fr/jcms/p_3473151/fr/dupixent-fasenra-nucala-tezspire-et-xolair-dans-le-traitement-de-l-asthme-severe
2023
France
guidelines for drug use
No Treatment for Diabetes
Nucala
Omalizumab
Borg Category-Ratio 10 Perceived Exertion Score 5
Omalizumab
Treat
tezspire
Treatment
Treatment Study
Severe Hallucination
Intensity and Distress 5
Severe Adverse Event
During Treatment
Epidermal cGVHD Score 4
Asthma
Dupilumab
asthma
Fasenra
Asthma Pathway
xolair
severe
Severe Dysplasia
asthma, nos
On Treatment
GDC Treatment Frequency Terminology
Treatment Epoch
Therapy Object
Dupixent
asthma
Biomaterial Treatment
Severe Extremity Pain
Mepolizumab
---
https://www.has-sante.fr/jcms/p_3380395/fr/nucala-mepolizumab-asthme-severe-a-eosinophiles-pour-les-enfants-de-6-ans-et-plus-et-les-adolescents
2022
France
evaluation of the transparency committee
mepolizumab
child, nos
mepolizumab
adolescence
severe
eosinophils
Asthma
Adolescent
asthma
Adolescent
child
Nucala
asthma
Child
Child
pulmonary eosinophilia
Eosinophilia
Child
eosinophilia
adolescent
Child
---
